Paracrine downstream targets collectively – no direct molecular binding

This entry represents a functional classification rather than a specific molecular entity, encompassing the diverse array of receptors and signaling pathways activated indirectly through paracrine mechanisms. In many advanced therapies, such as CAR-T cells or bispecific T-cell engagers, the primary drug-target interaction triggers a localized release of secondary signaling molecules like cytokines or growth factors (Nature Reviews Drug Discovery, 2019). These secondary messengers then act upon neighboring cells—even those not directly targeted by the drug—to amplify the immune response or alter the physiological state of the tissue (Journal of Hematology & Oncology, 2021). Because the drug does not physically bind to these downstream molecules, they are grouped collectively as indirect targets. This phenomenon, often called the bystander effect, is critical for the overall efficacy of treatments in heterogeneous environments like solid tumors (Nature Education, 2014). However, these indirect pathways are also the primary drivers of significant therapeutic challenges, including systemic inflammatory responses. Understanding these collective targets is essential for predicting clinical outcomes and managing toxicities like cytokine release syndrome (Blood, 2014). Thus, while not direct binding sites, these paracrine effectors are integral components of the drug's pharmacodynamic profile.

Other names

Paracrine signaling effectorsIndirect downstream targetsBystander effect mediatorsSecondary signaling pathways

Indirect modulation of cellular pathways via the release of secondary signaling molecules (e.g., cytokines, growth factors) following primary target engagement (Nature Education, 2014).